The Utility of Insulin Glargine (Lantus) Compared to NPH [insulin suspension isophane] in Ethnic Minority Type 2 Diabetic Subjects on Combination Insulin-Oral Agent Therapy

Trial Profile

The Utility of Insulin Glargine (Lantus) Compared to NPH [insulin suspension isophane] in Ethnic Minority Type 2 Diabetic Subjects on Combination Insulin-Oral Agent Therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Mar 2013

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin suspension isophane
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2011 Results published in the Diabetes Research and Clinical Practice.
    • 06 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Feb 2009 Planned end date changed from 1 Feb 2010 to 1 Aug 2009, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top